IBL-302

IBL-302 is an orally available, small molecule multikinase inhibitor that targets PIM kinases (PIM1, PIM2, and PIM3), phosphatidylinositol 3 kinase (PI3K), and mammalian target of rapamycin (mTOR) pathways. It was developed to overcome resistance mechanisms in cancer therapy by simultaneously inhibiting these key signaling nodes involved in tumor growth, survival, and drug resistance. Preclinical studies have demonstrated its efficacy against a range of cancers including neuroblastoma and breast cancer—particularly in models resistant to standard therapies such as trastuzumab. In neuroblastoma models, IBL‑302 induces apoptosis, promotes neuronal differentiation, reduces N‑Myc protein expression, and enhances the effects of chemotherapeutic agents like cisplatin. The compound has shown significant anti-tumor activity both as a single agent and in combination with chemotherapy in animal xenograft models[1][3][6].

Other names

IBL 302IBL302IBL-302